Introduction
The newly designated family Flaviviridae, of which yellow fever (YFV) virus is the prototype, consists of about 70 largely arthropod-borne enveloped viruses, many of which are important human pathogens (Westaway et al., 1985) . Although a safe, highly effective and inexpensive live attenuated vaccine against yellow fever has been available for over 50 years (Theiler & Smith, 1937) , conventional approaches have so far failed to provide similar vaccines against other flaviviruses of major medical importance, such as those causing dengue fever and Japanese encephalitis. The high degree of structural homology and antigenic relatedness among flaviviruses (Hahn et al., 1988) suggests that immunogenie characterization of vaccine strain YFV should be valuable in the development of other flavivirus vaccines. Immunity to YFV has generally been related to the presence of neutralizing antibodies against the virion envelope glycoprotein (E). However, it has recently been shown that passive transfer of monoclonal antibodies directed to a YFV non-virion glycoprotein, NS1 (previously designated soluble complement-fixing antigen NV3, gp48), protects mice against lethal YFV infection (Schlesinger et al., 1985; Gould et al., 1986) and that active immunization of mice and monkeys with NS1 provides similar protection (Schlesinger et al., 1985 . More recently, protective immunization of mice with recombinant YFV or dengue virus NS1 has been demonstrated as well (Cane & Gould, 1988; Bray et al., 1989) . The mechanism of such protection in the absence of anti-vifion antibody is unclear, but evidence that NS1 is associated with the plasma membrane (Stohlman et al., 1975; Cardiff &Lund, 1976) and an apparent correlation between protective and cytolytic capacities of anti-YFV NS1 antibodies (Schlesinger et al., 1985) suggest that protection might result from destruction of infected cells bearing surface NS1. Immune recognition of viral antigen on the surface of infected ccl~ has been postulated to play a role in host defence against infection by many other enveloped viruses (Sissons & Oldstone, 1980; Doherty & Zinkernagel, 1984; Cooper & Nemerow, 1986 ), but in these examples virion structural proteins inserted into the plasma membrane during virus budding rendered the infected cell susceptible to destruction by antibody or cell-mediated mechanisms. Although the precise events in fiaviviral morphogenesis are incompletely understood, cumulative evidence suggests that virus envelopment occurs in the cytoplasm and that 0000-9204 © 1990 SGM mature virus is released from the cell by exocytosis of virion-containing vesicles (Brinton, 1986; Ishak et al., 1988) . However, conflicting reports of flavivirus release by budding from the plasma membrane have also been presented (Ohyama et al., 1977; Hase et al., 1987) and plasma membrane-associated virion antigen has been detected by immunoelectron microscopy (Cardiff & Lund, 1976; Gould et al. 1985) Current interest in the development of recombinant flaviviral vaccines incorporating E and NS1 prompted additional study of the basis for protection conferred by antibody to these proteins. We report here on the further characterization of cell surface YFV NS1 and of the interaction of antibody with YFV NS1 and E on the cell. Monoclonal antibodies and antisera. The production and protective capacity of mouse monoclonal antibodies against YFV NS 1 and E and of mouse myeloma control proteins have been described (Schlesinger et al., 1983 (Schlesinger et al., , 1985 Brandriss et al., 1986) . Monoclonal immunoglobulins were used in the form of ascitic fluid. Serum specific for YFV NS 1 or E was prepared by hyperimmunization of rabbits with the respective immunoaffinity-purified proteins and characterized as reported earlier (Schlesinger et al., 1985; Brandriss et al., 1990) . Rabbit serum against YF NS1 had no neutralizing activity, but fixed complement to high titre (1:4096) in a conventional complement-fixing assay using sucrose-acetone-extracted, YFV-infected, suckling mouse brain. Rabbit serum against YFV E exhibited no complement-fixing activity in this assay, but did have a high titre (1:1024) of plaque-reducing, neutralizing activity against YFV. Antiserum to cell surface antigens of Neuro 2a or SWl3 cells was prepared in rabbits by multiple subcutaneous injections with the respective cells in Freund's adjuvant.
Methods

Virus
For radiobinding assays, monoclonal antibodies or control IgG2a myeloma protein PC5 were concentrated from ascitic fluid by ammonium sulphate precipitation and purified by Protein ASepharose CL-4B (Pharmacia) affinity chromatography (Ey et al., 1978) . Each protein was dialysed against phosphate-buffered saline (PBS) pH 7.2 and stored at 4 °C to avoid freezing-induced aggregation. SDS-PAGE of the purified monoclonal immunoglobulins revealed no contaminating proteins after Coomassie blue staining. Protein concentrations were determined spectrophotometrically with an extinction 1% coefficient E2,o °° of 14. Immunoglobulin solutions were centrifuged at 165000 g for 3 h and the upper one-third of the sample containing monomeric protein was used for radiobinding experiments. Proteins were radioiodinated by the iodogen method of Fraker & Speck (1978) and stored at 4 °C.
Polyacrylamide gel electrophoresis and Western blotting. Discontinuous SDS-PAGE was performed according to Laemmli (1970) . Western blotting was performed by the method of Towbin et al. (1979) using Immobilon paper (Millipore).
Immune cytolysis. A previously described complement-mediated cytolytic assay was used to determine the cytolytic capacity of monospecific antisera prepared to YFV NS1 or E (Schlesinger et al., 1985) . Briefly, target cells grown to confluence in 96-well microtest plates were infected with 17D YFV and labelled with Na251 CrO4 24 or 48 h later, at which time SWl3 and Neuro 2a cells, respectively, were uniformly infected. Labelled infected monolayers were incubated at 37°C for 2 h with heat-inactivated antibody and rabbit complement (1 : 20) before harvesting with a Titertek supernatant collection system. Assays were performed in quadruplicate and the standard error usually did not exceed 5 %. Percentage of specific lysis was calculated using the formula (experimental 51Cr release -spontaneous release)/(maximal release -spontaneous release) × 100 in which spontaneous release was determined with antibody and heat-inactivated complement and maximal release was the value obtained after detergent lysis of the cell monolayer.
To measure the effect of anti-YFV NS1 monoclonal antibody, or monospecific antiserum and complement on YFV propagation in vitro Neuro 2a or SW 13 cell monolayers were grown in 22 mm plastic Costar cluster plates and infected at 37°C with 17D YFV at an m.o.i, of 0-01 to 0.1. Residual virus was removed 1 h later by multiple washes. The medium was then replaced with MEM-10% FCS containing anti-YFV NS1 monoclonal antibody in the form of ascites or rabbit serum and active or heat-inactivated rabbit complement (1:20). A myeloma protein or preimmune rabbit serum added with and without complement served as a control. At 24 h intervals supernatant media were sampled for titration of infectious virus in a Vero cell plaque assay and active or heat-inactivated complement was replenished in the remaining wells to a final dilution of 1:20.
Immunoglobulin binding. Neuro 2a or SWl3 cells were grown and infected in 96-well microtest plates, as described for the cytolytic assay. Plates were washed twice with PBS to remove non-adherent cells and brought to 37 °C before addition of a constant amount of 12SI-labelled monoclonal antibody or myeloma protein (2 × 105 c.p.m., 0.03 ~tg) in 100 ~tl PBS-bovine serum albumin (BSA). Background uptake and specificity of binding was determined by measurement of the binding to uninfected cells and to infected cells in the presence of a large excess of unlabeUed homologous immunoglobulin. A highly efficient, rapid, multichannel microwell washer (Skatron) was used to deliver cold (4 °C) PBS for removal of unbound protein from the monolayers. The cells were then disrupted with lysing buffer and collected for determination of cell-associated radioactivity. The binding of monospecific rabbit antiserum against YFV E or NS1 to YFV-infected SW cells was determined in an indirect immunoassay, using radioiodinated Staphylococcus aureus Protein A as a probe. All assays were performed in quadruplicate and the standard error usually did not exceed 5%.
Cross-linking analysis of YFV-infected cells. BS 3 is a water-soluble, homobifunctional N-hydroxysuccinimide ester that can form 114 nm covalent bridges between closely adjacent protein lysine residues (Staros, 1982) . Because BS 3 is plasma membrane-impermeable it has been useful in the 'nearest neighbour' analysis of cell surface proteins (Lee & Conrad, 1985) . Infected SWI3 monolayers grown in 35 mm cluster plates were washed with cold 50 mM-HEPES-buffered 100 mMNaCI, pH 8.5 (cross-linking buffer) to remove non-adherent cells. Monolayers were treated with various amounts of BS 3 in cross-linking buffer for 30 min at 4 °C, after which 1 mM-glycine was added to stop the reaction. Residual reactants were removed by copious washing at 4 °C and the monolayers were solubilized with 50 mM-Tris-HC1 pH 7.4 containing 1% NP40 and mixed with Laemmli buffer containing no reducing agent. Electroblots of electrophoresed lysates were probed with monospecific rabbit anti-YFV NSI or E sera or rabbit serum against SW 13, followed by addition of radioiodinated S. aureus Protein A. Immunoaffinity-purified YFV NS1 (25 to 50 gg/ml cross-linking buffer) was treated with 1 mM-BS 3 and processed in parallel, to serve as a control.
Results
Immune cytolysis
The capacity of virion protein to subserve complementmediated cytotoxicity has been regarded as a measure of viral antigen fusion at the cell membrane (Fan & Sefton, 1978) . To compare the association of NS1 and E with the plasma membrane we tested monospecific rabbit anti-YFV NS1 and E sera for cytolytic activity, using YFVinfected Neuro 2a or SWl3 cells (Table 1) . Rabbit sera raised against the respective uninfected cells served as positive controls. Anti-NS1, but not E, antiserum sensitized infected cells to complement-mediated lysis. Similarly, no cytolytic activity was detected among 12 previously described protective IgG2a or IgG2b monoclonal anti-E antibodies (data not shown). Absence of cytolytic activity in rabbit anti-E sera could not be explained by an anti-complement effect, since there was no interference with the lyric activity of anti-SW 13 serum in mixing experiments (data not shown).
Interruption of virus spread by lysis of YFV-infected cells offers a possible mechanism for the protective effect of complement-fixing anti-NS1 antibody. To test this hypothesis the effect of anti-NS1 antibody (1A5) and complement on YFV proliferation in Neuro 2a and SW 13 cells was measured. The result of a representative experiment performed in duplicate is shown in Table 2 . Peak titres were usually reached at 48 h, when there was a 100-fold reduction in titratable virus from cells treated with complement-fixing monoclonal anti-NS1 antibody 1A5 and complement, and a 10-fold reduction with rabbit anti-YFV NS1 serum and active complement.
In parallel experiments YFV-infected Neuro 2a cell monolayers grown on glass coverslips were treated with monoclonal anti-NS1 antibody 1A5 or IgG2a myeloma protein PC-5 and complement. At various intervals cells were examined by phase contrast microscopy for c.p.e. and by immunofluorescence assays (IFA) for cellassociated antigen after acetone fixation. At 48 h postinfection no c.p.e, was seen under any treatment conditions and less than 5% of cells treated with monoclonal antibody 1A5 and complement were IFApositive, whereas 50 to 75 ~ of cells treated with antibody and inactivated complement or myeloma controls were IFA-positive. Monolayers'treated with antibody 1A5 and active complement were intact with minimal c.p.e. * Cells were infected for 1 h after which residual virus was removed and antibody (1:100) and complement (1:20) were added. PC5 is an IgG2a mouse myeloma and 1A5 an IgG2a anti-NS1 monoclonal antibody.
~" The symbols represent (-) heat-inactivated and (+) active. :[: log10 p.f.u./ml tissue culture supernatant at 48 h.
at 70 h post-infection, at which time the c.p.e, was complete under all other conditions. In similar assays three other previously described non-protective monoclonal anti-YFV NS1 antibodies (Schlesinger et al., 1985) , which do not fix complement, had no effect on virus production in the presence or absence or complement. One protective complement-fixing IgG2b anti-NS1 monoclonal antibody (8G4) had no effect on virus production in this assay.
Binding of monoclonal antibody to YFV-infected cells
For this assay the binding of a protective, neutralizing IgG2a monoclonal antibody (3El0) was compared with that of an IgG2a complement-fixing anti-NS1 monoclonal antibody (1A5). Specificity of binding was confirmed by the complete prevention of binding by homologous unlabelled monoclonal antibody. At 37 °C substantially more anti-NS1 than anti-E antibody appeared bound (Fig. l a) . At 4°C this difference was further exaggerated with marginal binding of anti-E antibody to YFV-infected SW13 cells and little or no binding of anti-E antibody to YFV-infected Neuro 2a cells, detected by radioimmuno-or indirect immunofluorescence assays (data not shown). In similar assays more monospecific anti-NS 1 than anti-E serum antibody bound to YFV-infected SW13 cells (Fig. l b) .
Cross-linking analysis
Earlier studies by Winkler et al. (1988) indicated that NS1 exists as a heat-labile dimer in flavivirus-infected cells. To test whether this form is represented on the plasma membrane we compared YFV-infected SW13 cells treated with the cell membrane-impertneable crosslinking reagent BS 3 to BS3-treated immunoaffinitypurified YFV NS1. NS1, a lysine-containing protein, should be susceptible to BS 3 cross-linking in its dimeric, but not monomeric, form. Fig. 2(a) shows results of BS 3 treatment of purified YF NS1. Unboiled untreated NS1 (lane 1) is represented by monomeric and polymeric forms, which, upon boiling, were seen in monomeric form only (lane 3). BS3-treated NS1 (lanes 2 and 4) largely retained the polymeric form, even upon boiling (lane 4). Similarly, polymeric NS1 predominated in unboiled lysates of YFV-infected SW13 cells (Fig. 2b,  lanes 1 to 4) , but only monomeric NS1 remained after boiling lysed untreated infected cells (lane 5). Treatment of the cell surface with increasing concentrations of BS 3 resulted in the formation of heat-stable polymerized NS 1 (lanes 6 to 8). Rabbit anti-SW 13 or monospecific rabbit anti-E sera failed to react with these high Mr bands, suggesting that they are homopolymers of NS1. Boiled cross-linked cell surface NS1 appeared as a triplet and migrated more slowly than the native NS1 homopolymer, perhaps due to exaggerated denaturation associated with the harsh treatment conditions. That most of the NS1 was present in monomeric form after boiling of the BS3-treated cells is consistent with the expectation that there would be a larger amount of NS1 within the cell than on the cell surface.
Discussion
We have previously shown complement-mediated lysis of YFV-infected cells by monoclonal anti-NS1 antibodies that protected mice against lethal intracerebral challenge with the virus (Schlesinger et al., 1985) . The results of the present study indicate that both NS1 and E proteins are present on the surface of infected cells, but that only antibody directed at NS1 sensitizes the cell to complement-mediated lysis. Binding studies employing anti-NS1 and anti-E monoclonal antibodies or monospe- cific antisera suggest that quantitative differences in cell surface density of NS1 and E may contribute to the observed divergence in cytolytic activity between antibodies to these proteins. Additionally, antibody bound to cell surface NS1, shown in these experiments to be present in polymeric form, might be expected to activate complement more efficiently than antibody to the E protein, since the affinity o f complement binding increases proportionately with immune complex size (Cooper, 1985) . Virus replication and spread among cells maintained in media containing cytolytic anti-NSl antibody and complement was markedly reduced, as measured by plaque assay as well as by immunofluorescence assay of infected cells, suggesting an in vitro correlation to protection conferred by passive administration of such antibody. It is possible that release of immature and possibly less infectious virus from complement-damaged cells interfered with the spread of virus to neighbouring uninfected cells. An explanation for the failure of one previously described (Schlesinger et al., 1985) protective IgG2b anti-NS1 complement-fixing antibody (8G4) to interfere with infection in this assay remains to be explored.
It is generally agreed that YFV, like other flaviviruses, is released from the cell by a mechanism other than budding (Brinton, 1986; Ishak et al., 1988) , so that the E protein is probably not integrated into the plasma membrane, a conclusion further supported by failure of the anti-E antibody to sensitize YFV-infected cells to complement-mediated cytolysis. Rather, immunoelectron microscopic study (Gould et al., 1985) has demonstrated binding of monoclonal anti-YFV E antibody to aggregates of mature virions, which had presumably accumulated on the cell after their release. Complement activated in this location might preferentially attack the virion envelope rather than plasma membrane. Recent studies have demonstrated simultaneous release of flaviviral E and NS1 from the cell (Lee et al., 1989) with extracellular NS1 recoverable in association with membranous particles, possibly in the form of membrane-bound dimers or multimers (Mason, 1989) . It has been further postulated that dimerization of NS1 provides the necessary hydrophobicity for membrane association (Winkler et al., 1989) . It is not known whether virion E and NS1 share a common pathway of maturation and release, but the fact that only anti-NS1 antibody appears to be cytolytic suggests that, whatever the process of virus release from the cell, NS1 is more intimately associated with the plasma membrane during the maturational process.
Because of the aberrant migration of both heated cross-linked purified and cell surface NS1 in the polyacrylamide gels it was difficult to assign a precise Mr to the NS 1 homopolymers, but it is likely that the dimeric form was represented. Accumulation of small amounts of immunoreactive NS1 protein at the stacking-running gel border further suggested that higher order homopolymers of purified or cell surface NS1 were also produced after BS 3 treatment. Our failure to detect any evidence of BS 3 cross-linking of cell surface E is consistent with the likelihood that the virion is loosely bound to the plasma membrane and is lost upon washing of the BS3-treated cells. That cross-linked E-NSI moieties were not detected further suggests that the proteins are not closely associated on the cell.
Taken together with earlier studies the present results are consistent with our hypothesis that humoral, and possibly cellular, recognition of cell surface NS 1 and the consequent cytolysis provides an alternative to virion neutralization by antibodies in the protection against flavivirus infection. Since infected cells might persist in the absence of an immune response to NSI, preference for a bivalent E-NS1 preparation has been urged in the design of future subunit flaviviral vaccines (Stephenson, 1988) .
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